Angiogenesis Inhibitors: A Detailed Analysis of Emerging Compounds is a comprehensive 150-page report that evaluates 52 inhibitors in or near clinical trials plus 13 different categories of compounds in pre-clinical development or research for the treatment of cancer, psoriasis, ophthalmic diseases, and arthritis. BioInsights estimates the probabilities of FDA approval for all 52 first and second generation inhibitors based on a comprehensive database of pre-clinical and clinical data, mechanism of action, estimated launch date, dosage, delivery, company support, and a "wild card" assessment for each compound. For the 19 compounds most likely to be approved, BioInsights estimates future revenues and net present values if the compounds are approved, and then calculates current valuations. The average valuation is $26 million, which indicates that this class of therapeutics is emerging and, as yet, unproven. There are many promising compounds, however, such as Combretastatin from Oxigene, Endostatin from EntreMed, ABX-IL8 from Abgenix, Thalidomide from Celgene, and SU101 from Sugen (Pharmacia & Upjohn). In addition, there are many promising next generation compounds and strategies such as naturally occurring inhibitors from Human Genome Sciences, vascular targeting peptides from Techniclone and ILEX Oncology, and small molecule inhibitors from Abbott Laboratories, Schering-Plough, and Warner-Lambert. In summary, this report details the emergence of three generations of angiogenesis inhibitors over the next five to ten years.